Can DIO1 and DIO2 variants affect T4 to T3 conversion and thyroid symptoms when free T4 is normal?

Standard thyroid testing often fails to explain persistent hypothyroid symptoms when thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels fall within normal ranges. Emerging research into deiodinase gene variations offers a molecular explanation for this clinical discrepancy.

Genetic and mechanistic pathways

• Enzymatic impairment: The DIO1 variant rs11206244 (minor T allele) and the DIO2 Thr92Ala (rs225014) polymorphism significantly reduce the activity of type 1 (D1) and type 2 (D2) deiodinases, the enzymes responsible for converting T4 into active T3.
• Intracellular T3 deficit: Because T3 is the primary hormone acting on nuclear receptors, impaired local conversion (especially via D2 in target organs like the brain) directly reduces tissue-specific thyroid signaling. This can trigger localized hypothyroid symptoms, such as fatigue and cognitive issues, even when circulating blood levels appear normal.
• Hormonal profile shifts: Decreased D1 activity impairs the clearance of reverse T3 (rT3), leading to lower Free T3/FT4 ratios and elevated circulating rT3 levels.

Clinical evidence and diagnostic utility

• Persistent symptoms: Approximately 10% to 15% of patients on T4 monotherapy report persistent symptoms like fatigue and weight fluctuations despite normal FT4 levels, which correlates with altered conversion efficiency.
• Diagnostic controversies: While low FT3 and elevated rT3 are biochemically linked to reduced deiodinase efficiency, major endocrine guidelines (such as the American Thyroid Association) advise against routine FT3 and rT3 testing. This is because rT3 is highly sensitive to non-thyroidal systemic stressors, which reduces its specificity as a direct marker for primary thyroid dysfunction.

Bottom line

• Genetic variants in Base DIO1 and DIO2 impair the peripheral conversion of T4 to T3, providing a plausible biological explanation for persistent hypothyroid symptoms when FT4 is normal. However, routine testing of FT3 and rT3 is not currently recommended by major clinical guidelines due to confounding systemic factors and a lack of established clinical utility.